Journal of the Neurological Sciences
Volume 264, Issue 1 , Pages 1-8 , 15 January 2008

Prion proteins: Physiological functions and role in neurological disorders

  • Wei Hu

      Affiliations

    • Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • ,
  • Bernd Kieseier

      Affiliations

    • Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
    • ,
  • Elliot Frohman

      Affiliations

    • Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • ,
  • Todd N. Eagar

      Affiliations

    • Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • ,
  • Roger N. Rosenberg

      Affiliations

    • Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • ,
  • Hans-Peter Hartung

      Affiliations

    • Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
    • ,
  • Olaf Stüve

      Affiliations

    • Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • Department of Neurology, Heinrich Heine University, Düsseldorf, Germany
    • Center for Immunology, University of Texas Southwestern Medical Center at Dallas, TX, United States
    • Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, United States
    • Corresponding Author InformationCorresponding author. Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX, United States 75390-9036. Tel.: +1 214 6488816; fax: +1 214 6489129.

Received 6 January 2007 ,Revised 1 May 2007 ,Accepted 8 June 2007.

References 

  1. Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515–1522
  2. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51(2):229–240
  3. Armstrong RA, Lantos PL, Cairns NJ. Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt–Jakob disease. Neuropathology. 2001;21(4):266–271
  4. Parchi P, Capellari S, Gambetti P. Intracerebral distribution of the abnormal isoform of the prion protein in sporadic Creutzfeldt–Jakob disease and fatal insomnia. Microsc Res Tech. 2000;50(1):16–25
  5. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt–Jakob disease using a highly sensitive immunoblotting assay. Lancet. 2001;358(9277):171–180
  6. Hilton DA, Sutak J, Smith ME, Penney M, Conyers L, Edwards P, et al. Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt–Jakob disease. J Clin Pathol. 2004;57(3):300–302
  7. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S, et al. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt–Jakob disease: an immunohistochemical, quantitative, and biochemical study. Am J Pathol. 2004;164(1):143–153
  8. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519–550
  9. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144
  10. Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol. 2006;4(10):765–775
  11. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, et al. Neurotoxicity of a prion protein fragment. Nature. 1993;362(6420):543–546
  12. Kunz B, Sandmeier E, Christen P. Neurotoxicity of prion peptide 106–126 not confirmed. FEBS Lett. 1999;458(1):65–68
  13. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science. 1996;274(5295):2079–2082
  14. Prusiner SB. The prion diseases. Brain Pathol. 1998;8(3):499–513
  15. Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363–13383
  16. Weissmann C. A ‘unified theory’ of prion propagation. Nature. 1991;352(6337):679–683
  17. Glatzel M, Ott PM, Linder T, Gebbers JO, Gmur A, Wust W, et al. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol. 2003;2(12):757–763
  18. Bruton CJ, Bruton RK, Gentleman SM, Roberts GW. Diagnosis and incidence of prion (Creutzfeldt–Jakob) disease: a retrospective archival survey with implications for future research. Neurodegeneration. 1995;4(4):357–368
  19. Poser S, Zerr I, Schroeter A, Otto M, Giese A, Steinhoff BJ, et al. Clinical and differential diagnosis of Creutzfeldt–Jakob disease. Arch Virol Suppl. 2000;(16):153–159
  20. Ironside JW. Pathology of variant Creutzfeldt–Jakob disease. Arch Virol Suppl. 2000;(16):143–151
  21. Montagna P. Fatal familial insomnia: a model disease in sleep physiopathology. Sleep Med Rev. 2005;9(5):339–353
  22. Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003;2(3):167–176
  23. Mastrianni JA. The prion diseases: Creutzfeldt–Jakob, Gerstmann–Straussler–Scheinker, and related disorders. J Geriatr Psychiatry Neurol. 1998;11(2):78–97
  24. Liberski PP, Budka H. Gerstmann–Straussler–Scheinker disease. I. Human diseases. Folia Neuropathol. 2004;42 Suppl B:120–140
  25. Windl O, Giese A, Schulz-Schaeffer W, Zerr I, Skworc K, Arendt S, et al. Molecular genetics of human prion diseases in Germany. Hum Genet. 1999;105(3):244–252
  26. Miyazono M, Kitamoto T, Doh-ura K, Iwaki T, Tateishi J. Creutzfeldt–Jakob disease with codon 129 polymorphism (valine): a comparative study of patients with codon 102 point mutation or without mutations. Acta Neuropathol (Berl). 1992;84(4):349–354
  27. Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P, et al. Fatal familial insomnia and familial Creutzfeldt–Jakob disease: disease phenotype determined by a DNA polymorphism. Science. 1992;258(5083):806–808
  28. Kitamoto T, Shin RW, Doh-ura K, Tomokane N, Miyazono M, Muramoto T, et al. Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt–Jakob disease. Am J Pathol. 1992;140(6):1285–1294
  29. Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, Johnson P, et al. Linkage of the Indiana kindred of Gerstmann–Straussler–Scheinker disease to the prion protein gene. Nat Genet. 1992;1(1):64–67
  30. Moore RA, Vorberg I, Priola SA. Species barriers in prion diseases—brief review. Arch Virol Suppl. 2005;(19):187–202
  31. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003;422(6927):80–83
  32. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001;98(17):9836–9841
  33. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt–Jakob disease. Arch Neurol. 2006;63(4):497–501
  34. Dermaut B, Croes EA, Rademakers R, Van den BM, Cruts M, Hofman A, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol. 2003;53(3):409–412
  35. Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B, Barcikowska M, et al. Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology. 2004;62(2):313–315
  36. Del Bo R, Comi GP, Giorda R, Crimi M, Locatelli F, Martinelli-Boneschi F, et al. The 129 codon polymorphism of the prion protein gene influences earlier cognitive performance in Down syndrome subjects. J Neurol. 2003;250(6):688–692
  37. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, Schellenberg GD, et al. Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol. 2005;58(6):858–864
  38. Grubenbecher S, Stuve O, Hefter H, Korth C. Prion protein gene codon 129 modulates clinical course of neurological Wilson disease. NeuroReport. 2006;17(5):549–552
  39. Merle U, Stremmel W, Gessner R. Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease. Arch Neurol. 2006;63(7):982–985
  40. Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, de Quervain DJ. The prion gene is associated with human long-term memory. Hum Mol Genet. 2005;14(15):2241–2246
  41. Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, Amouyel P. Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurology. 1998;51(3):734–737
  42. Croes EA, Dermaut B, Houwing-Duistermaat JJ, Van den BM, Cruts M, Breteler MM, et al. Early cognitive decline is associated with prion protein codon 129 polymorphism. Ann Neurol. 2003;54(2):275–276
  43. Basler K, Oesch B, Scott M, Westaway D, Walchli M, Groth DF, et al. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell. 1986;46(3):417–428
  44. Puckett C, Concannon P, Casey C, Hood L. Genomic structure of the human prion protein gene. Am J Hum Genet. 1991;49(2):320–329
  45. Pan KM, Stahl N, Prusiner SB. Purification and properties of the cellular prion protein from Syrian hamster brain. Protein Sci. 1992;1(10):1343–1352
  46. Hornshaw MP, McDermott JR, Candy JM, Lakey JH. Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun. 1995;214(3):993–999
  47. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, et al. The cellular prion protein binds copper in vivo. Nature. 1997;390(6661):684–687
  48. Stockel J, Safar J, Wallace AC, Cohen FE, Prusiner SB. Prion protein selectively binds copper(II) ions. Biochemistry. 1998;37(20):7185–7193
  49. Holscher C, Bach UC, Dobberstein B. Prion protein contains a second endoplasmic reticulum targeting signal sequence located at its C terminus. J Biol Chem. 2001;276(16):13388–13394
  50. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science. 1998;279(5352):827–834
  51. Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, et al. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell. 1990;61(1):185–192
  52. Antoine N, Cesbron JY, Coumans B, Jolois O, Zorzi W, Heinen E. Differential expression of cellular prion protein on human blood and tonsil lymphocytes. Haematologica. 2000;85(5):475–480
  53. Durig J, Giese A, Schulz-Schaeffer W, Rosenthal C, Schmucker U, Bieschke J, et al. Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br J Haematol. 2000;108(3):488–495
  54. Li R, Liu D, Zanusso G, Liu T, Fayen JD, Huang JH, et al. The expression and potential function of cellular prion protein in human lymphocytes. Cell Immunol. 2001;207(1):49–58
  55. Burthem J, Urban B, Pain A, Roberts DJ. The normal cellular prion protein is strongly expressed by myeloid dendritic cells. Blood. 2001;98(13):3733–3738
  56. Krebs B, Dorner-Ciossek C, Schmalzbauer R, Vassallo N, Herms J, Kretzschmar HA. Prion protein induced signaling cascades in monocytes. Biochem Biophys Res Commun. 2006;340(1):13–22
  57. Weissmann C, Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Br Med Bull. 2003;66:43–60
  58. Bader M. Transgenic animal models for neuropharmacology. Rev Neurosci. 2000;11(1):27–36
  59. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356(6370):577–582
  60. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol. 1994;8(2–3):121–127
  61. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73(7):1339–1347
  62. Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol. 1999;292(4):797–817
  63. Sakaguchi S, Katamine S, Nishida N, Moriuchi R, Shigematsu K, Sugimoto T, et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature. 1996;380(6574):528–531
  64. Rossi D, Cozzio A, Flechsig E, Klein MA, Rulicke T, Aguzzi A, et al. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J. 2001;20(4):694–702
  65. Silverman GL, Qin K, Moore RC, Yang Y, Mastrangelo P, Tremblay P, et al. Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein. Expression in testis and ectopic production in the brains of Prnp(0/0) mice predisposed to Purkinje cell loss. J Biol Chem. 2000;275(35):26834–26841
  66. Nishida N, Tremblay P, Sugimoto T, Shigematsu K, Shirabe S, Petromilli C, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest. 1999;79(6):689–697
  67. Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell. 1998;93(2):203–214
  68. Race RE, Priola SA, Bessen RA, Ernst D, Dockter J, Rall GF, et al. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron. 1995;15(5):1183–1191
  69. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, et al. Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J. 1997;16(20):6057–6065
  70. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM, et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med. 1998;4(12):1429–1433
  71. Raeber AJ, Sailer A, Hegyi I, Klein MA, Rulicke T, Fischer M, et al. Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci U S A. 1999;96(7):3987–3992
  72. Jouvin-Marche E, Attuil-Audenis V, Aude-Garcia C, Rachidi W, Zabel M, Podevin-Dimster V, et al. Overexpression of cellular prion protein induces an antioxidant environment altering T cell development in the thymus. J Immunol. 2006;176(6):3490–3497
  73. Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996;15(6):1255–1264
  74. Brown HR, Goller NL, Rudelli RD, Merz GS, Wolfe GC, Wisniewski HM, et al. The mRNA encoding the scrapie agent protein is present in a variety of non-neuronal cells. Acta Neuropathol (Berl). 1990;80(1):1–6
  75. Makrinou E, Collinge J, Antoniou M. Genomic characterization of the human prion protein (PrP) gene locus. Mamm Genome. 2002;13(12):696–703
  76. McLennan NF, Rennison KA, Bell JE, Ironside JW. In situ hybridization analysis of PrP mRNA in human CNS tissues. Neuropathol Appl Neurobiol. 2001;27(5):373–383
  77. Mange A, Milhavet O, Umlauf D, Harris D, Lehmann S. PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Lett. 2002;514(2–3):159–162
  78. Santuccione A, Sytnyk V, Leshchyns'ka I, Schachner M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol. 2005;169(2):341–354
  79. Chen S, Mange A, Dong L, Lehmann S, Schachner M. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol Cell Neurosci. 2003;22(2):227–233
  80. Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, et al. Prions prevent neuronal cell-line death. Nature. 1999;400(6741):225–226
  81. Roucou X, Gains M, LeBlanc AC. Neuroprotective functions of prion protein. J Neurosci Res. 2004;75(2):153–161
  82. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem. 2001;276(42):39145–39149
  83. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001;2(1):63–67
  84. Roucou X, LeBlanc AC. Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med. 2005;83(1):3–11
  85. Marciano PG, Brettschneider J, Manduchi E, Davis JE, Eastman S, Raghupathi R, et al. Neuron-specific mRNA complexity responses during hippocampal apoptosis after traumatic brain injury. J Neurosci. 2004;24(12):2866–2876
  86. Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR, Linden R. Cellular prion protein transduces neuroprotective signals. EMBO J. 2002;21(13):3317–3326
  87. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, et al. Signal transduction through prion protein. Science. 2000;289(5486):1925–1928
  88. Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann O. NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 2003;100(23):13326–13331
  89. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science. 2004;303(5663):1514–1516
  90. Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke. 2006;37(5):1296–1300
  91. Sakurai-Yamashita Y, Sakaguchi S, Yoshikawa D, Okimura N, Masuda Y, Katamine S, et al. Female-specific neuroprotection against transient brain ischemia observed in mice devoid of prion protein is abolished by ectopic expression of prion protein-like protein. Neuroscience. 2005;136(1):281–287
  92. Shyu WC, Lin SZ, Chiang MF, Ding DC, Li KW, Chen SF, et al. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci. 2005;25(39):8967–8977
  93. Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, et al. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis. 2005;20(2):442–449
  94. Chacon MA, Barria MI, Lorca R, Huidobro-Toro JP, Inestrosa NC. A human prion protein peptide (PrP(59–91)) protects against copper neurotoxicity. Mol Psychiatry. 2003;8(10):853–862[835]
  95. Colling SB, Khana M, Collinge J, Jefferys JG. Mossy fibre reorganization in the hippocampus of prion protein null mice. Brain Res. 1997;755(1):28–35
  96. Colling SB, Collinge J, Jefferys JG. Hippocampal slices from prion protein null mice: disrupted Ca(2+)-activated K+currents. Neurosci Lett. 1996;209(1):49–52
  97. Manson JC, Hope J, Clarke AR, Johnston A, Black C, MacLeod N. PrP gene dosage and long term potentiation. Neurodegeneration. 1995;4(1):113–114
  98. Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, et al. Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia. 1999;40(12):1679–1682
  99. Tobler I, Gaus SE, Deboer T, Achermann P, Fischer M, Rulicke T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature. 1996;380(6575):639–642
  100. Coitinho AS, Roesler R, Martins VR, Brentani RR, Izquierdo I. Cellular prion protein ablation impairs behavior as a function of age. NeuroReport. 2003;14(10):1375–1379
  101. Criado JR, Sanchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, et al. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis. 2005;19(1–2):255–265
  102. Martinez dH, Lopez-Bravo M, Metharom P, Ardavin C, Aucouturier P. Prion protein expression by mouse dendritic cells is restricted to the nonplasmacytoid subsets and correlates with the maturation state. J Immunol. 2006;177(9):6137–6142
  103. Ballerini C, Gourdain P, Bachy V, Blanchard N, Levavasseur E, Gregoire S, et al. Functional implication of cellular prion protein in antigen-driven interactions between T cells and dendritic cells. J Immunol. 2006;176(12):7254–7262
  104. de Almeida CJ, Chiarini LB, da Silva JP, Martins ES, Linden MA. The cellular prion protein modulates phagocytosis and inflammatory response. J Leukoc Biol. 2005;77(2):238–246
  105. Politopoulou G, Seebach JD, Schmugge M, Schwarz HP, Aguzzi A. Age-related expression of the cellular prion protein in human peripheral blood leukocytes. Haematologica. 2000;85(6):580–587
  106. Mabbott NA, Brown KL, Manson J, Bruce ME. T-lymphocyte activation and the cellular form of the prion protein. Immunology. 1997;92(2):161–165
  107. Mattei V, Garofalo T, Misasi R, Circella A, Manganelli V, Lucania G, et al. Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett. 2004;560(1–3):14–18
  108. Bainbridge J, Walker KB. The normal cellular form of prion protein modulates T cell responses. Immunol Lett. 2005;96(1):147–150

PII: S0022-510X(07)00400-5

doi: 10.1016/j.jns.2007.06.019

Journal of the Neurological Sciences
Volume 264, Issue 1 , Pages 1-8 , 15 January 2008

Article Tools

* Image Usage & Resolution